

The Company Announcements Platform

ASX Limited

By E-lodgement

Intellectual Property Update

Melbourne, Australia, 27 October 2015: Prescient Therapeutics (ASX:PTX) a clinical stage oncology company, has further strengthened its intellectual property portfolio with the granting of a key US patent protecting lead cancer drug PTX-200.

The US Patent and Trademark Office has issued patent No. 9,150,604 covering PTX's proprietary method for treating esophageal cancer, as well as its method for sampling tumours to determine levels of overexpression of a key cancer causing protein known as AKT kinase.

High AKT expression is associated with a poor outlook, resistance to chemotherapy and shortened survival times in a range of cancers.

PTX's lead product PTX-200 is a novel small molecule that works by blocking the AKT signaling pathway, and inhibiting tumour growth in a range of cancers.

Further, deactivating the AKT pathway has been shown to markedly increase the sensitivity and even reverse resistance of esophageal cancer cells to chemotherapeutic drugs. Key trials of PTX-200 are currently underway in the United States in a range of cancers.

PTX Executive Director Mr Paul Hopper said this new patent further secured the Company's proprietary rights to its lead product PTX-200, which is a highly promising drug candidate offering a targeted approach.

He said the Company recently reported a clinical update from an ongoing Phase 1b/2 Investigator Sponsored Trial of PTX-200 in breast, lung and oesophageal cancer.

Under the Phase 1b study protocol, fifteen patients with advanced cancer have been treated with PTX-200 in combination with weekly paclitaxel chemotherapy, with researchers noting evidence of anti-tumour activity.

Dose escalation of PTX-200 has proceeded to the third and final dose level. Researchers expect to initiate an expansion cohort in 12 patients at the recommended Phase 2 dose to better characterise the safety profile of the combination.

Worldwide, esophageal cancer is the sixth most common cause of cancer-related death.

Mr Hopper added: "The incidence of esophageal cancer continues to rise in both Australia and the United States. There is a great unmet need for new therapies that may work alongside or independently of existing drugs for improved outcomes.

"This patent strengthens our commercial position as we investigate the efficacy of our drug as a potential new treatment in a range of cancers."

Ends.

About Prescient Therapeutics (PTX)

PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors..

PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Paul Hopper
Executive Director
+61 406 671 515

Rudi Michelson
Monsoon Communications
+61 (0) 3 9620 3333